144
Participants
Start Date
January 31, 2013
Primary Completion Date
February 28, 2015
Study Completion Date
May 31, 2015
Tasquinimod
A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
Placebo
Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
AZ Maria Middelares, Ghent
UZ Gent, Ghent
Leuven
Roeselare
Prague
Prague
Brno
Olomouc
Prague
Aalborg
Aarhus
Copenhagen
Herlev
Angers
Bordeaux
Clermont-Ferrand
Dijon
Lille
Besancon, Lyon
Centre Leon Berard, Lyon
Hopital Edouard Herriot, Lyon
Paris
Saint-Herblain
Toulouse
Villejuif
Aachen
Essen
München
Nürtingen
Tübingen
Bajcsy-Zsilinszky Kórház, Budapest
Országos Onkológia Intézet, Budapest
Uzsoki utcai Kórház, Budapest
Genova
Milan
Modena
Pavia
Roma
Rozzano
Torino
Kaunas
Vilnius
Gdansk
Gdynia
Olsztyn
Urology and Urological Oncology Department and Clinic, Wroclaw
Wojewódzki Szpital Specjalistyczny we Wrocławiu, Wroclaw
Hospital Clinic Vllarroel, Barcelona
Hospital del Mar, Barcelona
Hospital Valle de Hebrón, Barcelona
Elche
Sabadell
Valencia
Leeds
Guy's & St Thomas NHS Foundation, London
The Royal Marsden NHS Trust, London
University College Hospitals London, London
Sutton
Lead Sponsor
Ipsen
INDUSTRY